Alzheimer's Disease Drug Pipeline: Success or failure of clinical trials for Alzheon's Alzheimer's drug candidates significantly impacts investor confidence.

Financial Performance: Alzheon's revenue, earnings, and cash flow influence investor perception of its long-term viability.

Regulatory Approval: Receipt of regulatory approvals (e.g., FDA in the US, EMA in Europe) for Alzheon's drugs is a major price driver.

Market Sentiment: Overall investor sentiment towards pharmaceutical stocks, especially those focused on Alzheimer's disease, can affect ALZ.F.

Competition: The competitive landscape, including progress by other companies developing Alzheimer's treatments, influences ALZ.F's valuation.

Partnerships & Funding: Major partnerships, collaborations, or successful funding rounds can positively affect the stock price.

Economic Conditions: General economic conditions and macroeconomic factors (e.g., interest rates, inflation) can impact investment decisions.

News & Public Opinion: News related to Alzheimer's research, awareness campaigns, and public perception of Alzheon can also play a role.